Ophthalmic Imaging Using Adaptive Optics and OCT

描述(由申请人提供)： 该BRP的目的是开发和评估新的仪器，该仪器将允许对人类视网膜中的单细胞，特别是视杆细胞和视锥感光细胞以及神经节细胞进行前所未有的三维成像。一个跨学科的团队将结合自适应光学(AO)和光学相干断层扫描(OCT)，为视网膜成像提供最佳的横向分辨率。将使用互补的OCT成像方式、泛光照明和面部扫描开发两种仪器。这些仪器将用于研究与正常衰老、老年性黄斑变性(AMD)和青光眼相关的细胞形态。这些仪器将被定量地相互比较，并与现有的视网膜成像设备进行比较。该项目将由加州大学戴维斯分校(UC-Davis COCD)领导，在那里与劳伦斯·利弗莫尔国家实验室(LLNL)合作开发了一套高性能的AO系统。这一合作将扩大到包括LLNL和印第安纳大学(IU)的OCT专家团队。印第安纳大学的团队此前通过自适应光学中心与LLNL合作，并已经开发出用于视网膜成像的工作原型AO-OCT系统。在这个BRP项目中，LLNL将在UCD现场建造一台AO-OCT仪器，以便在3-5年进行临床测试，而第二台AO-OCT仪器将在伊利诺伊大学与LLNL合作开发，并于4-5年在实验室进行测试。在UCD和IU将获得AO-OCT和功能测量的比较。这两种仪器都将提供给不属于BRP的科学家和临床医生使用，并将在项目期间进行改进。UCD在视觉科学、衰老以及AMD和青光眼进展和治疗的评估方面拥有专业知识LLNL在用于天文学的AO研究方面有着悠久的历史，并已将其一些AO技术转移到UCD的视觉科学。LLNL还拥有OCT方面的专业知识，并率先将其应用于口腔和血管结构的活体成像。伊利诺伊大学的团队在光学光学和视网膜电生理学方面拥有丰富的光学光学和视觉科学经验。这个BRP得到了顾问的支持，他们在德克萨斯大学和Carl Zeiss Meditec开发了眼科OCT技术。蔡司集团已经通过商业开发将OCT技术转移到临床，并将为我们的AO-OCT系统整合用户友好的界面提供便利。因此，该BRP结合了工程师、视觉科学家和临床医生的独特专业知识，他们具有共同工作的经验，实现了从实验室到应用的平稳过渡。这个协同团队将开发新一代仪器来推进视觉科学，允许在体内研究视网膜功能障碍，从而为正常衰老、青光眼和黄斑变性的发病机制提供新的见解，并提供一种可靠的方法来监测视网膜疾病的新治疗方法。

DESCRIPTION (provided by applicant): The purpose of this BRP is to develop and evaluate new instrumentation that will permit unprecedented three dimensional imaging of single cells in the human retina, specifically rod and cone photoreceptors and ganglion cells. An interdisciplinary team will combine adaptive optics (AO), enabling the best lateral resolution for retinal imaging, with optical coherence tomography (OCT), providing the best axial resolution for retinal imaging. Two instruments will be developed using complementary OCT imaging modalities, flood illumination and enface scanning. These instruments will be used to study cellular morphology associated with normal aging, age-related macular degeneration (AMD) and glaucoma. The instruments will be compared quantitatively with each other and with existing retinal imaging devices. The project will be led by UC-Davis COCD), where a high-performance AO system has been developed in collaboration with the Lawrence Livermore National Laboratory (LLNL). This collaboration will be expanded to include a team of OCT experts at LLNL and Indiana University (IU). The IU team has previously collaborated with LLNL through the Center for Adaptive Optics and has already developed a working prototype AO-OCT system for retinal imaging. In this BRP project, LLNL will construct one AO-OCT instrument at the UCD site to be tested clinically in years 3-5, while the second AO-OCT instrument will be developed at IU in collaboration with LLNL and tested in the laboratory in years 4-5. Comparisons of AO-OCT and functional measures will be obtained at UCD and IU. Both instruments will be made available for use by scientists and clinicians who are not part of the BRP, and will be refined through the course of the project period. UCD has expertise in vision science, aging, and evaluation of AMD and glaucoma progression and treatment LLNL has a long history of research on AO for astronomy and has transferred some of its AO technology to vision science at UCD. LLNL also has expertise in OCT, and has pioneered its application to in vivo imaging of oral and vascular structures. The IU team has experience in AO-OCT and vision science with specific expertise in visual optics and retinal electrophysiology. This BRP is buttressed by consultants who have developed ophthalmic OCT technology at the University of Texas and Carl Zeiss Meditec. The Zeiss group has already transferred OCT technology to the clinic via commercial development and will facilitate incorporation of user friendly interfaces for our AO-OCT systems. This BRP thus combines the unique expertise of engineers, vision scientists and clinicians who have experience working together to effect a smooth transition from the laboratory to applications. This synergistic team will develop a new generation of instruments to advance vision science, permit retinal dysfunction to be studied in vivo in a way that will offer new insights into normal aging, the pathogenesis of glaucoma and macular degeneration, and a reliable method to monitor novel treatments for retinal disease.